Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester Comprehensive Cancer Center. The findings will be presented Dec. 6, 2025, at the American Society of Hematology (ASH) annual meeting in Orlando.

According to a new trial, patients with chronic lymphocytic leukemia show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed period of time.

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received chemotherapy-based conditioning or total body irradiation (TBI), the standard conditioning regimen used before hematopoietic cell transplantation. The findings could allow more patients to avoid TBI and its associated long-term side effects.

Nearly a third of families with children receiving chemotherapy for acute lymphoblastic leukemia (ALL) – the most common pediatric cancer – develop serious financial difficulties during their child’s treatment, including losing 25% or more of their household income and struggling to cover the costs of basic living expenses such as housing, food, and utilities.